FOSUN HEALTH Logo

Melanoma Diagnosis

catalogue

Melanoma Diagnosis

Melanoma Diagnosis

Melanoma is diagnosed by examining a suspicious lesion with a dermatoscope and then removing it for the pathologist to examine. The diagnosis is not made from the appearance alone, because the finding that governs treatment — how far the melanoma has grown into the skin — can only be measured on tissue. The assessment then moves to the lymph nodes for melanomas above the guideline thickness threshold, and to imaging when the risk of spread makes it worthwhile.

Examining the skin: what a dermatoscope adds

The assessment of a pigmented lesion is a comparison rather than a pattern match, and the instrument that makes it reliable is the dermatoscope — a magnifying device with a light that shows structures within the lesion:

  • The examination is about the person, not only the lesion — a melanoma is often the lesion that looks different from the others, so the scalp, the soles, between the toes and the nails are all examined.
  • Dermoscopic photography is used where several lesions need watching, so that the next comparison is against a recorded image rather than memory.
  • A lesion that cannot be classified confidently is removed rather than observed — a few days of pathology settle a question that months of watching would not.

Removing the lesion: why the whole thing is taken

For a suspicious skin lesion the standard diagnostic procedure is an excisional biopsy — the whole lesion removed with a narrow margin of normal skin, usually two to three millimetres — because the pathologist must be able to see the deepest point and the surrounding skin:

  • A shave or small punch can make the thickness unmeasurable — it may remove the superficial part and leave the deepest part behind, which is the measurement that decides treatment.
  • A partial sample is used deliberately in specific sites — a large lesion, or one on the face or a digit, where an incisional biopsy or a full-thickness punch establishes the diagnosis before the definitive operation is planned.
  • Under a nail the biopsy is of the matrix — the nail is lifted and the pigmented tissue sampled, which is why it is a small operation; damage to the nail afterwards is expected and preferable to a melanoma treated as an infection.

The pathology report: the measurements that decide the plan

The report written by the pathologist is the central document in melanoma, because it contains information no other test provides. These are the items that need to be there:

  • Breslow thickness — the distance in millimetres from the top of the granular layer to the deepest melanoma cell; it sets the excision margin and the threshold for staging the nodes.
  • Ulceration — whether the surface has broken down, recorded separately because it makes a melanoma behave less favourably than its thickness alone would predict.
  • Mitotic rate — how many cells were seen dividing, which adds to the assessment particularly for thinner melanomas.
  • Margins — whether the melanoma was removed completely, and how close it comes to the edge; an involved margin is why a further excision is planned.
  • Microsatellites, lymphovascular and perineural invasion — small deposits beyond the lesion and involvement of vessels or nerves, all of which are additional unfavourable findings.
  • Melanoma in situ is reported separately — the cells are confined to the epidermis, so there is no thickness to measure; it is treated by complete removal with a small margin.

Staging the lymph nodes: the sentinel node biopsy

One test answers directly whether the melanoma has reached the nodes that drain the area: the sentinel lymph node biopsy, in which a tracer and a dye identify the first draining node for the pathologist to examine in detail.

  • It is offered by thickness rather than by preference — broadly for melanomas thicker than about 0.8 mm, and where ulceration or another unfavourable feature makes the risk worth measuring.
  • It is usually done with the wider excision, so the conversation belongs before that operation is planned.
  • A positive result changes the conversation, not the immediate operation — the options are removing the remaining nodes in that basin or close ultrasound surveillance, weighed against the risk of lymphoedema.
  • Where a node is already enlarged and melanoma is confirmed in it, the operation becomes treatment rather than staging, and treatment after surgery is usually discussed at the same time.

Imaging: when it is needed, and what it is looking for

Imaging does not diagnose a melanoma of the skin — that is done with a dermatoscope and a biopsy. Its role is to look for spread, and it is used selectively, because for a thin melanoma the chance of finding anything is low:

  • Ultrasound of the node basins examines the nodes that drain the site, guides a needle sample of an abnormal node, and is the method of surveillance where dissection is not chosen.
  • CT and PET-CT survey the organs where melanoma most often appears, and are used for melanomas at higher risk of spread or where symptoms suggest it.
  • MRI of the brain is used where spread to the brain is a concern, since the brain is a site melanoma reaches more often than most cancers.
  • LDH in the blood is part of assessing advanced disease rather than a screening test, since the level reflects how much melanoma is present.

Tests on the tissue, and what is genuinely used to choose treatment

The melanoma tissue already in the laboratory is the source of the tests that decide whether targeted drug treatment is available, which means the answer rarely depends on another procedure:

  • BRAF is the test that most often changes the plan — where it is present, a BRAF inhibitor combined with a MEK inhibitor becomes an option after surgery and for advanced disease.
  • KIT is tested particularly in acral and mucosal melanomas, and NRAS is checked because it explains why some melanomas do not respond to BRAF-directed treatment.
  • Melanoma that began inside the eye follows a different pathway, which is one reason uveal melanoma is managed with its own protocols.
  • No blood test diagnoses melanoma or reliably detects recurrence, and genetic testing of the person is not part of choosing treatment outside specific family circumstances.

How the plan is put together

Melanoma is a disease in which a small number of findings decide a great deal, so the plan is built in a defined order rather than assembled from parallel opinions:

  • The pathology comes first — thickness, ulceration, mitotic rate and margins decide the operation, and the node staging is discussed at the same time so that both are done together.
  • The tissue markers come next, deciding whether a targeted option exists alongside the immune-based one; asking for them at the outset avoids the delay of obtaining them when a decision is urgent.
  • The whole picture is reviewed at one meeting — pathology, surgery, medical and radiation oncology looking at the same material, with surveillance planned for years rather than months.

Frequently Asked Questions

Does a biopsy make the melanoma spread?

No. There is no established evidence that taking a biopsy, removing a lesion or injuring a mole causes melanoma to spread, and the biopsy is a diagnostic step rather than a risk. The concern usually comes from the sequence: a melanoma that has been growing quietly is often noticed around the time a lesion is removed or knocked. Being examined early is what allows a melanoma to be measured while it is thin. If a lesion has been removed elsewhere without being sent for examination, mention it, because the pathology is worth having.

What is Breslow thickness, in plain terms?

It is a measurement in millimetres taken under the microscope — the distance from the top of the granular layer of the epidermis down to the deepest melanoma cell. It is the most useful measurement in melanoma because it describes what the melanoma has done rather than what it looks like, and it decides two things: how much normal skin is removed around it, and whether the draining nodes are staged. It can only be measured on tissue removed whole, which is why a surface sample can leave the question unanswerable.

If the sentinel node biopsy is positive, has the melanoma spread?

It means the melanoma has reached the first draining node — regional disease, or stage III — which is not the same as spread to another organ. That distinction matters because stage III melanoma is often treated with the intention of controlling it, using further treatment after surgery, and the node basin is dealt with either by removing the remaining nodes or by ultrasound surveillance at intervals. The recommendation depends on the size of the deposit, the number of nodes involved and what matters to you, since dissection carries a risk of lymphoedema in the limb.

How long does it take to get a diagnosis?

Days rather than weeks for the pathology itself, since the tissue removed at biopsy is processed and reported, and the report is the point at which the diagnosis is made. What takes longer is the sequence that follows: a wider excision with or without a node biopsy is planned as a second operation once the report is available, and the node result takes a little longer again because the node is examined in more detail. Tissue marker tests are usually completed within the same period. It is reasonable to ask for the report and the marker results in writing.

Send the pathology and the marker results, get a written plan

Upload the full pathology report with Breslow thickness, ulceration, mitotic rate and margins, the slides or a link to scanned images where a review is useful, any BRAF, KIT or NRAS results, the imaging with its reports and dates, and the record of any treatment already given. Our team will return a written assessment within 48 hours of the file being complete, setting out what the pathology means, which operations or tests are still needed, and what the treatment and follow-up plan would be.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*